Novo Nordisk shares dipped after the EU approved a 7.2 mg dose of Wegovy for obesity. Clinical data showed a 21% weight loss over 18 months. The approval offers doctors greater flexibility, allowing three 2.4 mg injections per week. The move comes as Novo Nordisk protects its market share against competitors.